Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | PKM | P14618 | 1/20 | 0.57 |
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | STS | P08842 | 1/20 | 0.48 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.45 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.44 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4248138 | 0.96 | KDM4E (0.60) | KDM4EPKMGPR119GAATHRB | |
| SCHEMBL9023290 | 0.89 | KDM4E (0.55) | KDM4EPKMGPR119GAATHRB | |
| SCHEMBL15477388 | 0.86 | SMN1; SMN2 (0.48) | PKMSMN1; SMN2 | |
| SCHEMBL8444736 | 0.85 | KDM4E (0.59) | KDM4EPKMGPR119GAATHRB | |
| SCHEMBL5453826 | 0.84 | GPR119 (0.51) | KDM4EPKMGPR119THRB | |
| SCHEMBL23329642 | 0.83 | ALDH1A1 (0.59) | KDM4EPKMGPR119STSTGFBR1 | |
| SCHEMBL17942453 | 0.83 | GPR119 (0.51) | KDM4EPKMGPR119TGFBR1MEN1 | |
| SCHEMBL25572016 | 0.82 | TGFBR1 (0.52) | KDM4EPKMGPR119THRBSTS | |
| SCHEMBL1474954 | 0.80 | KDM4E (0.53) | KDM4EPKMGPR119GAATHRB | |
| SCHEMBL7872006 | 0.80 | KDM4E (0.58) | KDM4EPKMGPR119GAATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150025057-A1 | Triazine-oxadiazoles | NOVARTIS AG (CH) | 2015-01-22 | — | — | US | disclosed |
| EP-2616465-A1 | TRIAZINE-OXADIAZOLES | Novartis AG (CH) | 2013-07-24 | — | — | EP | disclosed |
| WO-2012035023-A1 | TRIAZINE-OXADIAZOLES | NOVARTIS AG (CH) | 2012-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150025057-A1 | Triazine-oxadiazoles | OPRK1, OPRD1, OPRL1 | KDM4E 3067/4885PKM 1412/4885GPR119 474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.